Molecular Diversity, Год журнала: 2024, Номер 29(1), С. 215 - 239
Опубликована: Апрель 28, 2024
Язык: Английский
Molecular Diversity, Год журнала: 2024, Номер 29(1), С. 215 - 239
Опубликована: Апрель 28, 2024
Язык: Английский
Bioorganic Chemistry, Год журнала: 2024, Номер 149, С. 107483 - 107483
Опубликована: Май 21, 2024
Язык: Английский
Процитировано
7RSC Medicinal Chemistry, Год журнала: 2024, Номер 15(3), С. 981 - 997
Опубликована: Янв. 1, 2024
Novel chloropyridazine hybrids as promising anticancer agents acting by apoptosis induction and PARP-1 inhibition through a molecular hybridization strategy.
Язык: Английский
Процитировано
6Journal of Molecular Liquids, Год журнала: 2023, Номер 386, С. 122460 - 122460
Опубликована: Июнь 29, 2023
Язык: Английский
Процитировано
15Chemistry & Biodiversity, Год журнала: 2024, Номер 21(11)
Опубликована: Июль 26, 2024
Pyrazole and its derivatives remain popular heterocycles in drug research, design, development. Several drugs include the pyrazole scaffold, such as ramifenazone, ibipinabant, antipyrine, axitinib, etc. They have been extensively studied by scientific community are said to a wide range of biological activity, especially anticancer agents targeting EGFR. Overexpression EGFR signalling promotes tumor growth inhibiting apoptosis. dysfunction has described multiple cancers, including colon, head neck, NSCLC, liver, breast, ovarian cancer. As result, represents prospective target for cancer treatment. anti-EGFR thriving, notably dacomitinib, afatinib, erlotinib, gefitinib, osimertinib. However, almost all currently available limited therapeutic effectiveness due lack selectivity well substantial side effects. Furthermore, aberrant across numerous human malignancies/carcinomas is impeded gene amplification, protein overexpression, mutations, or in-frame deletions, making EGFR-induced treatment challenging. To overcome such, novel with high efficacy minimal toxicity required. battle resistance inhibitors, pyrazole, pyrazoline, their investigated viable pharmacophore development new better potency, lesser toxicity, favourable pharmacokinetic characteristics. The present investigation covers examination progress toward anti-cancer therapies via fused pyrazole-based compounds. current study also inclusive data on marketed candidates undergoing preclinical clinical Lastly, we discussed recent advances medicinal chemistry significance eradication various cancers provide direction structure-activity relationship (SAR), mechanistic studies.
Язык: Английский
Процитировано
5Molecular Diversity, Год журнала: 2024, Номер 29(1), С. 215 - 239
Опубликована: Апрель 28, 2024
Язык: Английский
Процитировано
4